🇨🇦 BNT162b7 Monovalent (OMI BA.4/BA.5) in Canada

BNT162b7 Monovalent (OMI BA.4/BA.5) (bnt162b7-monovalent-omi-ba-4-ba-5) regulatory status in Canada.

Marketing authorisation

BNT162b7 Monovalent (OMI BA.4/BA.5) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in Canada

Frequently asked questions

Is BNT162b7 Monovalent (OMI BA.4/BA.5) approved in Canada?

Yes. Health Canada has authorised it.

Who is the marketing authorisation holder for BNT162b7 Monovalent (OMI BA.4/BA.5) in Canada?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.